Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
13/09/202222:20TipRanksAnalysts Conflicted on These Healthcare Names: Horizon Therapeutics (HZNP) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
12/09/202214:25TipRanksRobert W. Baird Releases a Hold Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
09/09/202206:01GlobeNewswire Inc.Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022NASDAQ:NTLAIntellia Therapeutics Inc
02/09/202206:55Dow Jones NewsIntellia Therapeutics' NTLA-2002 Genome Candidate Receives FDA's Orphan Drug DesignationNASDAQ:NTLAIntellia Therapeutics Inc
02/09/202206:01GlobeNewswire Inc.Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
26/08/202222:16TipRanksBMO Capital Remains a Hold on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
23/08/202223:59GlobeNewswire Inc.Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin SymposiumNASDAQ:NTLAIntellia Therapeutics Inc
09/08/202214:11TipRanksWhich 3 ARK Innovation Stocks Can Bounce the Most?NASDAQ:NTLAIntellia Therapeutics Inc
09/08/202202:00TipRanksAnalysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Crispr Therapeutics AG (CRSP)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202222:35TipRanksIntellia Therapeutics (NTLA) Receives a Hold from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
05/08/202214:53TipRanksAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Bicycle Therapeutics (BCYC) and OrthoPediatrics (KIDS)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202213:38TipRanksRobert W. Baird Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202208:45TipRanksIntellia Therapeutics (NTLA) Gets a Buy Rating from Chardan CapitalNASDAQ:NTLAIntellia Therapeutics Inc
05/08/202206:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
04/08/202221:47Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
04/08/202221:30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
27/07/202221:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
27/07/202219:08TipRanksSVB Securities Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
28/06/202200:35TipRanksIntellia Therapeutics (NTLA) Receives a Buy from William BlairNASDAQ:NTLAIntellia Therapeutics Inc
27/06/202223:16TipRanksIntellia Therapeutics (NTLA) Gets a Hold Rating from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
26/06/202220:05TipRanksIntellia Therapeutics (NTLA) Gets a Buy Rating from Brookline Capital MarketsNASDAQ:NTLAIntellia Therapeutics Inc
25/06/202201:40TipRanksChardan Capital Thinks Intellia Therapeutics’ Stock is Going to RecoverNASDAQ:NTLAIntellia Therapeutics Inc
24/06/202221:46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
24/06/202221:31PR Newswire (US)Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single DoseNASDAQ:NTLAIntellia Therapeutics Inc
24/06/202221:30GlobeNewswire Inc.Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single DoseNASDAQ:NTLAIntellia Therapeutics Inc
24/06/202202:45TipRanksJMP Securities Thinks Intellia Therapeutics’ Stock is Going to RecoverNASDAQ:NTLAIntellia Therapeutics Inc
22/06/202223:25TipRanksAnalysts Offer Insights on Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
17/06/202208:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
17/06/202208:41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
17/06/202208:36Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA